Back to News
Market Impact: 0.4

UBS lowers Wendy’s stock price target to $9.50 on US sales challenges

UBSWENSMCIAPP
Company FundamentalsAnalyst InsightsCorporate EarningsCorporate Guidance & OutlookCapital Returns (Dividends / Buybacks)Consumer Demand & RetailProduct Launches
UBS lowers Wendy’s stock price target to $9.50 on US sales challenges

Wendy's (WEN) is navigating a challenging market, with UBS lowering its price target to $9.50 from $11.00 while maintaining a Neutral rating, citing pressured U.S. same-store sales and macroeconomic headwinds, despite solid international performance and the stock's 51% decline over the past year. The company recently reported better-than-expected Q3 same-store sales and adjusted EBITDA but maintained full-year guidance, leading to mixed analyst reactions; while Truist reiterated a Buy rating, several firms including BMO, Bernstein, Evercore, and RBC reduced their price targets due to ongoing turnaround challenges and earnings visibility concerns, even as Wendy's updated its free cash flow forecast upwards and pursues initiatives for anticipated sales improvements by 2026.

Analysis

UBS lowered its price target for Wendy's (WEN) to $9.50 from $11.00, maintaining a Neutral rating, citing macroeconomic and competitive headwinds impacting US same-store sales. This adjustment comes as WEN trades near its 52-week low of $8.39, having declined over 51% in the past year. Despite these pressures, the company reported better-than-expected Q3 adjusted EBITDA of $138 million, surpassing the $123 million consensus. Wendy's reiterated its 2025 guidance for global same-store sales decline (3-5%) and adjusted EPS ($0.82-0.89), but notably improved its free cash flow (FCF) forecast to $195-210 million from $160-175 million, alongside reduced capital expenditure guidance. This FCF improvement aligns with a strong 14% LTM FCF yield and is supported by aggressive share buybacks and a 6.24% dividend yield. Analyst sentiment remains mixed, with Truist reiterating a Buy rating and increasing estimates, while BMO, Bernstein, Evercore, and RBC reduced price targets due to turnaround challenges and earnings visibility concerns. UBS anticipates Q4 challenges but expects sales improvements through 2026, driven by initiatives like the chicken tenders launch and Project Fresh. The firm views WEN's valuation as undemanding at approximately 10 times 2026 EBITDA, contingent on a strengthening sales trajectory and improving FCF growth.